Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Reversal of Residual Neuromuscular Blockade After Neostigmine and Half-dose Sugammadex: A Comparison With Standard Reversal of Full-dose Neostigmine

NCT05066035 is registered in ClinicalTrials.gov with Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital as lead sponsor.

NCT NCT05066035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05066035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Reversal of Residual Neuromuscular Blockade After Neostigmine and Half-dose Sugammadex: A Comparison With Standard Reversal of Full-dose Neostigmine
Lead sponsor
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Phase
Phase 4
Overall status
Completed
Start date
May 1, 2013
Completion date
December 30, 2016
Enrollment
113 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

complication of anesthesia, neostigmine, neuromuscular blockade, postoperative residual curarization, rocuronium, sugammadex